Back to Journals » OncoTargets and Therapy » Volume 9

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

Total article views   HTML views PDF downloads Totals
5,946 Dovepress* 5,515+ 1,159 6,674
PubMed Central* 431 230 661
Totals 5,946 1,389 7,335
*Since 30 June 2016
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
3 0 0 0 1 2

View citations on PubMed Central and Google Scholar